EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Obstructive Sleep Apnea and Type 2 Diabetes: An Update

Sandro Gentile iD, Vincenzo Maria Monda, Giuseppina Guarino, Ersilia Satta, Maria Chiarello, Giuseppe Caccavale, Edi Mattera, Raffaele Marfella iD, Felice Strollo iD

Journal of Clinical Medicine · 07.08.2025 · 14 (15) · 5574

DOI: 10.3390/jcm14155574 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 07.08.2025. Verfasst von Sandro Gentile und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision Medicine, Vanvitelli University of Naples, 80131 Naples, Italy. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obstructive sleep apnea (OSA) syndrome is a severe, debilitating, and pervasive sleep disorder. OSA mainly affects people with obesity, type 2 diabetes mellitus (T2DM), hypertension, and dyslipidemia and is strongly associated with cardiovascular complications. Based on the bidirectional relationship between T2DM and OSA, the latter represents a risk factor for the former, and, vice versa, people with T2DM have a high risk of OSA. Mechanical and hormonal factors, inflammatory mediators, and a dysregulated autonomic nervous system contribute to the mechanisms underlying the disease. Treatment of OSA is necessary even if the available remedies are not always effective. In addition to traditional treatments, including lifestyle adaptations and bariatric surgery, CPAP equipment, i.e., a breathing device ensuring continuous positive pressure to keep the airways open during sleep, represents the most common treatment tool. More recently, pharmacological research has paved the way to newer seemingly effective therapeutic strategies involving, in particular, two hypoglycemic agent classes, i.e., sodium–glucose co-transporter 2 inhibitors (SGLT2-is) and glucagon-like peptide-1 (GLP-1) receptor agonists (GLP1-ras). This narrative review provides an update on all of the above.

Schlagwörter

Stichwörter der Autor:innen

cardiovascular riskobesityobstructive sleep apneasleep disorderstype 2 diabetes

Autor:innen und Institutionen

  • Department of Precision Medicine, Vanvitelli University of Naples, 80131 Naples, Italy.
  • Research Department, Nefrocenter Research Network, 80059 Torre del Greco, Italy.
  • Diabetes Unit ''Santissima Annunziata'' Hospital Cento, 44042 Ferrara, Italy.
  • Department of Advanced Medical and Surgical Sciences (DAMSS), Vanvitelli University of Naples, 80138 Naples, Italy.
  • Department of Endocrinology and Metabolic Diseases, IRCCS San Raffaele Pisana, 00163 Rome, Italy.

ORCID-Profile: Sandro Gentile, Raffaele Marfella, Felice Strollo

Zitieren

APA

Gentile, S., Monda, V. M., Guarino, G., Satta, E., Chiarello, M., Caccavale, G., Mattera, E., Marfella, R., & Strollo, F. (2025). Obstructive Sleep Apnea and Type 2 Diabetes: An Update. Journal of Clinical Medicine, 14(15), 5574. https://doi.org/10.3390/jcm14155574

Vancouver

Gentile S, Monda VM, Guarino G, Satta E, Chiarello M, Caccavale G, et al. Obstructive Sleep Apnea and Type 2 Diabetes: An Update. Journal of Clinical Medicine. 2025;14(15):5574. doi:10.3390/jcm14155574

BibTeX
@article{Gentile2025,
  author = {Gentile, Sandro and Monda, Vincenzo Maria and Guarino, Giuseppina and Satta, Ersilia and Chiarello, Maria and Caccavale, Giuseppe and Mattera, Edi and Marfella, Raffaele and Strollo, Felice},
  title = {Obstructive Sleep Apnea and Type 2 Diabetes: An Update},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {15},
  pages = {5574},
  doi = {10.3390/jcm14155574}
}
Kostenlos starten →